Skip to main
VERU
VERU logo

Veru (VERU) Stock Forecast & Price Target

Veru (VERU) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veru Inc. has shown strong potential in its drug development programs, highlighted by the successful initial topline results from the Phase 2b QUALITY trial, which could align with FDA's expectations for upcoming Phase 3 design discussions. The company's focus on metabolic diseases and solid management experience enhances its credibility, suggesting a strategic shift that could provide growth opportunities, despite certain risks associated with its flagship product, Enobosarm. Furthermore, the forecast of profitability by 2029, coupled with its focused niche pipeline, indicates a positive long-term outlook for Veru's financial performance.

Bears say

Veru Inc faces significant risks that may adversely affect its future financial performance, primarily stemming from volatility in industry fundamentals related to customer demand and pricing for its biopharmaceutical products. The presence of major competitors and potential shifts in market share or new product developments could negatively influence investor sentiment towards the company. Additionally, any unforeseen developments concerning the company's management, financial condition, or accounting practices could result in a detrimental effect on its valuation, contributing to an overall negative outlook.

Veru (VERU) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veru (VERU) Forecast

Analysts have given Veru (VERU) a Buy based on their latest research and market trends.

According to 2 analysts, Veru (VERU) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veru (VERU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.